Skin cancer is one of the most common cancers, which is divided into two major groups, melanoma and non-melanoma skin cancers (NMSCs). Melanoma is the major cause of death from skin cancer ([@bib36]) and considered as one of the most therapy-resistant malignancies ([@bib13]). If left untreated, NMSCs also can become destructive, invading local tissues and causing disfigurement ([@bib30]).

Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have received increasing attention owing to their possible anticancer effects ([@bib34]; [@bib5]; [@bib44]).

According to a meta-analysis of 16 randomized control trials (RCTs) before 2009 ([@bib1]), no association was found between statins and melanoma. Several observational studies also presented that statins have not identified anticancer effects ([@bib27]; [@bib26]). However, other recent observational studies showed that statins may be associated with a lower risk of melanoma ([@bib15]; [@bib20]). Thus, the effect of statins on the skin cancer risk remains to be determined.

Materials and Methods
=====================

Selection criteria
------------------

The studies considered in this meta-analysis were RCTs, case--control or cohort studies that evaluated exposure to statins and risk of skin cancer (including melanoma and NMSCs). The following inclusion criteria had to be fulfilled: (1) clearly defined and evaluated exposure to statins; (2) skin cancer incidence as the outcome of interest; (3) reported RR or odds ratio (OR) with 95% CI or provided data for their calculation. Studies reporting different measures of RR such as risk ratio, rate ratio, hazard ratio and OR were included because in practice they yield a similar RR estimate, given the absolute risk of skin cancer is low.

Identifying studies
-------------------

Broad searches were conducted to identify all published literatures and meeting abstracts in Pubmed (-2013) and Web of Science (1985--2013) limited to those human subjects without limitation on language. Search terms included 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA reductase inhibitor), statin, atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pravastatin, pitavastatin, rivastatin, rosuvastatin, simvastatin, combined with melanoma or non-melanoma or cancer or neoplasm or malignancy. Flow diagram is shown in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}. The detail of data collection is shown in [Supplementary Material 1](#sup1){ref-type="supplementary-material"}.

Quality assessment
------------------

The criteria adapted from the Cochrane handbook for systematic reviews of interventions ([@bib17]) and the validated Newcastle--Ottawa scale (NOS) ([@bib43]) were used to assess the methodological quality of RCTs, case--control and cohort studies, respectively.

Statistical analysis
--------------------

Study-specific risk estimates were extracted from each article, and log risk estimates were weighted by the inverse of their variances to obtain a pooled risk estimate. Heterogeneity was assessed by using Cochrane Q statistic and estimating *I*^2^ ([@bib18]). A fixed-effect model (Mantel--Haenszel) was used to calculate the pooled ORs when the test for heterogeneity was not statistically significant (*P*\>0.10), otherwise the random-effect model (DerSimonian and Laird) was employed ([@bib37]). Evidence of publication bias was determined using funnel plot and Egger\'s statistical test ([@bib8]). Subgroup analyses were carried out by quality of study methodology, study design and duration of statin use. Sensitivity analyses were conducted to evaluate the robustness of meta-analysis results ([@bib41]). Cumulative meta-analysis was conducted to identify the change in trend of reporting risk over time. Statistical analyses were performed using STATA 12.0 (STATA Corporation, College Station, TX, USA).

Results
=======

Characteristics of included studies
-----------------------------------

A total of 21 articles with 29 studies were identified, among which 24 studies focused on melanoma, whereas 14 studies reported NMSCs and 3 studies did not specify the classification of skin cancer ([Table 1](#tbl1){ref-type="table"}).

With respect to melanoma, 17 studies were *post-hoc* analyses or RCTs, 5 were case--control studies, and 2 were cohort studies. A total of 8433 cases of melanoma were cumulatively reported in 414 627 patients, and 114 708 individuals were classified as statin users. Concerning the NMSCs, 12 studies were *post-hoc* analyses or RCTs, 1 was case--control study and 1 was cohort study, of which 3354 cases and 99 906 controls were eligible.

Quality assessment results
--------------------------

The qualities of studies were moderate to high ([Table 1](#tbl1){ref-type="table"}).

Melanoma
--------

The association between statins and melanoma risk was not statistically significant assuming a random-effect model (RR, 0.94; 95% CI, 0.85--1.04). However, moderate heterogeneity was observed (*P*=0.07\<0.1; *I*^*2*^=33.8%). The funnel plot was symmetric and no publication bias was observed using Egger\'s test (*P*=0.95).

Subgroup analysis (see [Supplementary Table 1](#sup1){ref-type="supplementary-material"}) represented that none of the stratifications (study design, location and study duration) could account for the heterogeneity observed in the overall analysis. Regarding long-term statin use in particular, the results did not materially change (RR, 0.93; 95% CI, 0.73--1.18). Cumulative meta-analysis showed no significant change in trend of reporting risk from positive to negative.

NMSCs
-----

The statin use with increased NMSCs was not statistically significant no matter assuming a fixed-effect model (RR, 1.12; 95% CI, 1.05--1.20) or a random-effect model (RR, 1.03; 95% CI, 0.90--1.19). The Cochran\'s Q-test had a *P*-value of 0.007, and *I*^2^ was 61.7%, indicating there was moderate heterogeneity within the group. The *P* values for the Egger\'s test were 0.16, showing no evidence of publication bias.

Subgroup analysis showed that the results were not substantially changed by study design. In the sensitivity analysis, we identified the study by [@bib39]) and [@bib15]) contributed most to the between-study variability.

RR estimates and 95% CIs are listed in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}.

Discussion
==========

There are debates regarding the association between statin use and skin cancer.

One view is that the immunomodulatory effects of statins may impair the host antitumor immune response by suppressing tumor-specific effector T-cell response, therefore leading to an increased cancer risk ([@bib14]). Notably, immunosuppression represents an emerging risk factor for NMSCs. The immunomodulatory pleiotropic actions of statins resemble the immune phenotype, which predicts risk for post-transplantation NMSCs ([@bib29]; [@bib2]; [@bib28]). In addition, immunosuppressive actions of statin therapy may in part be related to increasing risk of a rare and aggressive neuroendocrine skin cancer, Merkel cell carcinoma ([@bib22]; [@bib33]).

On the contrary, in several *in vitro* and *in vivo* pre-clinical models of melanoma, statins have been presented to involve in anticancer activity ([@bib34]; [@bib5]; [@bib19]). They may have anticancer effects through targeting on HMGCR and the mevalonate pathway, which have a role in the metabolic reprogramming of cancer ([@bib3]; [@bib4]).

This meta-analysis showed no evidence that statin use is associated with a substantially decreased or increased risk of skin cancer (neither melanoma nor NMSCs). The results were not significantly affected by study design, study location and long-term statin use, which reinforce our confidence in the validity of the conclusion. Our findings are in line with recent meta-analyses on the association between statin use and melanoma ([@bib10]; [@bib1]). However, unlike *in vitro* and animal studies, meta-analyses do not demenstrate an effect of statins in humans, it is possible because of the inconsistent dosage and drug concentrations, some malignant cell lines are not inhibited by the same concentrations of statins achieved in humans ([@bib10]).

Moderate heterogeneity was identified in our meta-analysis, which should be considered with caution. There may be several factors contributing to the heterogeneity. The first reason is the multiple criteria for the diagnosis of skin cancer, which may introduce spectrum-of-disease bias. Second, detailed information for the type of statins was not provided, which made it hard to further investigate the potential difference between lipophilic and hydrophilic statins.

There could be several potential limitations in this meta-analysis. First, skin cancer (melanoma or NMSCs) was not the primary end point of the included RCTs; we were not able to obtain primary data regarding skin cancer diagnosis for all study participants. Second, even though the included studies had acceptable quality, detailed information of confounding factors was not provided (such as family history, skin color and sun exposure). To minimize the risk of misleading conclusions led by the lack of confounder control, we extracted adjusted RRs for different confounding factors whenever available. The third aspect deals with the varied definitions of drug exposure among eligible studies. [@bib20]) divided the participants into 'former user\', 'current use\' and 'no reported use\' groups, whereas in other studies, participants were identified as statin users or non-statin users.

However, the present study has several strengths. First of all, 21 articles with 29 studies were included, reporting data of 11 787 skin cancer cases. No exclusion criteria of language, location or study quality were applied. With large numbers of incident cases, meta-analysis could provide high statistical power. Moreover, no evidence of substantial publication bias was observed. Furthermore, the findings were similar in subgroup analysis of RCTs, case--control and cohort studies, although the methodological differences of original studies may introduce potential biases. In addition, even though moderate heterogeneity was observed, summary estimates were substantially unchanged after excluding the studies introducing most to the heterogeneity.

Two aspects should be noted in future studies. The potential use of statins for skin cancer prevention, especially melanoma, and the utility of testing statins as therapy in combination with chemotherapy are needed. In addition, because of the widespread use of statins, extending follow-up periods to identify potential effects on skin cancer in the longer-term statin use might be useful.

In conclusion, the meta-analysis indicates that there is no association between statin use and skin cancer risk on the basis of the findings of RCTs, case--control and cohort studies.
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###### Characteristics of included studies assessing the risk of skin cancer with statin use

  **Author, year**                                **Statin type**                 **Study design**             **Study quality**   **Location**                                **Time period**                                                                                            **Outcome assessment**                                                                                                                                  **Duration from statin treatment start and diagnosis**
  ----------------------------------------------- ------------------------------- ---------------------------- ------------------- ------------------------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@bib26]                                        a, f, pr, r, s                  Case--control                High                Taiwan                                      Recruitment from 01 January 2000 to 31 December 2008                                                       Investigated with the corresponding ICD-9-CM codes                                                                                                      Statin continuously used for at least 6 months before the index date (date of diagnosis and equivalent date for controls).
  [@bib25]                                        a, c, f, pr, r, s               Case--control                High                Netherland                                  Recruitment from 01 January 1991 to 14 December 2004                                                       The researchers extracted and recorded diagnosis and date of primary CM                                                                                 One or more statins for at least 6 months of cumulative prescription duration in the 3 years before CM.
  [@bib24]                                        NR                              Case--control                High                The United States                           Recruitment from 1990 to 2002                                                                              NR                                                                                                                                                      Received a prescription for a statin within the year before the index date, and their first prescription was recorded more than a year before the index date.
  [@bib15]                                        a, c, f, l, pr, r, s            Case--control                High                Finland                                     Recruitment from 01 January 1996 to 31 December 2005                                                       Obtained from Finnish cancer registry                                                                                                                   At least one prescription of any prescription of any statin between 1 January 1996 and 31 Dec 2005 and had no cancer diagnosis at the date of first purchase.
  [@bib11]                                        s                               Case--control                Moderate            Switzerland                                 1985--2007; follow-up was performed until December 2010                                                    Defined as the detection of any malignant tumor                                                                                                         Statin therapy was initiated, usually 3--12 months after transplantation in patients who recieve transplants after 1995 until the occurrence of malignancy or the end of the follow-up period.
  [@bib9]                                         a, f, l, pr, s                  Cohort                       Moderate            The United States                           Recruitment from 01 January 1997 to 31 December 2005                                                       A physician blinded to medication use reviewed 300 random charts with a new ICD-9-CM code for cancer from patients who were included in our analyses.   Beginning 2 years after his or her entry date and continuing until the first occurrence of the first appearance of cancer, 1 year after the last date that a prescription was filled for a medication of interest, death or the end of the analysis period.
  [@bib6]                                         a, f, l, pr, r, s               Case--control                High                The United States                           Recruitment from 15 March 2004 to 18 June 2007; follow-up begin from 1997 end in 2007                      Telephone questionnaire                                                                                                                                 Taking the drug at least once weekly within a year preceding the interview.
  [@bib23]                                        a, f, l, s (exclude c, pr, r)   Cohort                       Moderate            Canada                                      Recruitment from 01 April 1998 to 31 March 2004; follow-up through 31 March 2005                           Hospitalization with cancer                                                                                                                             Followed from hospital discharge until the occurrence of the study outcome, end of follow-up (31 March 2005).
  [@bib20]                                        f, l, pr, s                     Cohort                       High                The United States                           Recruitment from 1992 to 1993; follow-up begin from 1997 end in 2007                                       Self-administrated questionnaire                                                                                                                        Questionnaire asked participants to report whether they had taken any cholesterol-lowering drugs regularly during the past year.
  [@bib27]                                        NR                              Cohort (retrospective)       High                The United States                           Recruitment from 01 January 1990 to 28 February 2009                                                       Diagnosis of cancer recorded in the medical record after time zero                                                                                      Time zero was defined as the point at which patients began to take statins or, if never on statins, the date of the first recorded low-density lipoprotein or total cholesterol level in the database.
  [@bib42]                                        a, c, f, pr, r, s               Nested case--control         High                The United Kingdom                          01 January 1998--01 January 2008                                                                           NR                                                                                                                                                      At least 2 prescriptions in the 60-month period (or the 98-month period for the 10-year analysis).
  Officers *et al* (2002)                         pr                              RCT follow-up                                    Australia and New Zealand                   Recruitment from April 1990 to December 1992                                                               All deaths and AM1 are reviewed by the outcome assessment committee                                                                                     Supplies of open label pravastatin were provided to patients for a mean of 2 years beyond the end of the RCT.
  [@bib38]                                        a                               RCT                                              Sweden                                      Enrolled from February 1998                                                                                Adverse event reporting                                                                                                                                 Safety analysis was performed after 6 months and again after 2 years.
  [@bib35]                                        pr                              RCT                                              Scotland                                    Recruitment 01 February 1989 to 30 September 1991                                                          Based on subjects recall, further information was obtained from hospital records                                                                        5 years.
  [@bib32]                                        pr                              RCT                                              Canada and the United States                Recruitment from 04 December 1989 to 31 December 1991 ended between 01 January 1996 and 14 February 1996   NR                                                                                                                                                      The median duration of follow-up was 5.0 years.
  [@bib21]                                        a, c, f, l, pr, r, s            RCT                                              The United States                           Recruitment 01 October 1993 to 31 December 1998; follow-up through 20 September 2010                       Centrally adjudicated and SEER-coded cases                                                                                                              Cancer diagnoses were updated in the observational study or semiannually in the RCT by mail and/or telephone questionnaires.
  Heart Protection Study Collaborative G (2005)   s                               RCT                                              The United Kingdom                          Recruitment from July 1994 to May 1997                                                                     Question participants and review the calendar-packed tablets remaining                                                                                  Mean duration of follow-up was 5.0 years.
  [@bib12]                                        pr                              RCT                                              Italy                                       Recruitment from October 1993 to September 1995                                                            NR                                                                                                                                                      23 months
  [@bib7]                                         l                               RCT                                              The United States                           Recruitment from 30 May 1990 to 12 February 1993                                                           NR                                                                                                                                                      At least 5 years of follow-up.
  [@bib40]                                        s                               RCT follow-up                                    Denmark, Finland, Iceland, Norway, Sweden   Recruitment from 19 May 1988 to 16 August 1989 follow-up end at 01 August 1994                             Classified by an independent end point committee with hospital records                                                                                  A 2-year, interim follow-up study.
  [@bib39]                                        f                               8 RCTs (post hoc analyses)                       Multicenter                                 NR                                                                                                         NR                                                                                                                                                      NR

Abbreviations: CM=cutaneous melanoma; NR=not reported; RCT=randomized control trial.

NOS score into three levels (high quality, score ⩾7; moderate quality, 4⩽ score \<7; low quality, score \<4).

###### Summary of adjusted RRs assessing the risk of melanoma with statin exposure

                                                                                **All subjects**   **On statins**   **Not on statins**                   
  ----------------------------------------------- -------- ------ ------ ------ ------------------ ---------------- -------------------- -------- ------ ---------
  [@bib21]                                        Long     1.14   0.91   1.43   1200               119 726          89                   8824     1111   110 902
  [@bib27]                                        Short    1.08   0.85   1.37   259                10 309           136                  5215     123    5094
  [@bib20]                                                                      1251               133 255          411                  28 950   840    104 305
  [@bib20]                                        Long     0.79   0.66   0.96                                                                             
  [@bib20]                                        Short    0.89   0.75   1.06                                                                             
  [@bib20]                                        Former   0.64   0.46   0.89                                                                             
  [@bib6]                                                  0.97   0.73   1.29   400                1000             109                  276      291    724
  [@bib6]                                         Short    1.12   0.79   1.6                                                                              
  [@bib6]                                         Long     0.84   0.48   1.48                                                                             
  [@bib39]                                        Short    0.40   0.10   1.55   10                 6801             3                    3512     7      3289
  Heart Protection Study Collaborative G (2005)   Long     1.66   0.78   3.54   27                 20 536           17                   10 269   10     10 267
  [@bib38]                                        Short    0.35   0.01   8.39   1                  143              0                    70       1      73
  [@bib12]                                        Short    0.33   0.01   8.16   1                  4271             0                    2138     1      2133
  [@bib7]                                         Long     0.52   0.27   0.99   41                 6605             14                   3304     27     3301
  [@bib32]                                        Long     1.33   0.30   5.94   7                  4159             4                    2081     3      2078
  [@bib35]                                        Long     0.67   0.19   2.35   10                 6595             4                    3302     6      3293
  [@bib9]                                         NR       0.84   0.7    1.02   540                62 842           304                  37 248   236    25 594
  [@bib24]                                        NR       2.5    0.8    7.3    26                 459              7                    79       19     380
  [@bib25]                                        Short    0.98   0.78   1.2    1318               8104             96                   599      1222   7505
  [@bib40]                                        Long     1.29   0.48   3.45   16                 4444             9                    2221     7      2223
  Officers *et al* (2002)                         Short    1.08   0.69   1.7    77                 9014             39                   4512     38     4502
  [@bib42]                                        Short    1.04   0.87   1.23   3249               16 364           433                  2108     2816   14 256

Abbreviations: CI=confidence interval; NR=not reported; RR=relative risk.

###### Summary of adjusted RRs assessing the risk of skin cancer (except melanoma) with statin exposure

                                                                    **All subjects**   **On statins**   **Not on statins**                  
  --------------------------- -------------- ------ ------- ------- ------------------ ---------------- -------------------- -------- ----- --------
  [@bib27]                    Non-melanoma   0.98   0.81    1.19    394                10 309           197                  5215     197   5094
  [@bib15]                    Non-melanoma   1.28   1.16    1.41    1735               50 294           990                  25 445   745   24 849
  Strandberg *et al* (2004)   Non-melanoma   1.04   0.62    1.74    57                 4444             29                   2221     28    2223
  [@bib11]                    NR             0.76   0.49    1.18    61                 255              32                   151      29    104
  [@bib23]                    NR             0.88   0.55    1.41    75                 30 076           26                   11 338   49    18 738
  [@bib26]                    NR             1.62   0.662   3.875   88                 34 205           12                   6841     76    27 364
  [@bib12]                    Non-melanoma   1.00   0.06    15.94   2                  4271             1                    2138     1     2133
  [@bib7]                     Non-melanoma   1.03   0.87    1.22    493                6605             250                  3304     243   3301
  [@bib39]                    Non-melanoma   0.77   0.60    1.00    228                6801             103                  3512     125   3289
  [@bib38]                    Non-melanoma   1.20   1.00    1.45    445                20 536           243                  10 269   202   10 267

Abbreviations: CI=confidence interval; NR=not reported; RR=relative risk.
